Goldman Sachs maintained a Neutral rating on Mindray Medical (NYSE: MR) with a price target of $30.10 (from $30.80). Comments follow Q2 results. Analyst Wei Du said, "China revenue growth continued to decelerate 3.4% yoy to US$152.5 mn, as hospitals were . ... ...

18 people liked this